glp 1 receptor agonist agent Frontiers Semaglutide vs. Other GLP-1 Receptor
Description
Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.
The preliminary data on the effect of GLP-1 RAson asthma in patients with diabetes are promising and merit further trials and research studies.
Otolaryngologist patients with medullary thyroid cancer should not be taking GLP-1 medications at this time due to the risk.
This drug, indicated for glycemic control in patients aged 10 years and above with type 2 diabetes, serves as an adjunct to diet and exercise
Data Synthesis Twenty-two reports and six prescribing sheets were included
